MRNA
What one share of Moderna holds
Biological Products, (No Diagnostic Substances)
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more.
Moderna’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.66 |
|---|---|
| Profit | −$8.01 |
| Capex (buildings and equipment) | $0.43 |
| Free cash flow | −$3.16 |
| Cash and investments | $4.32 |
| Debt | $1.57 |
| Book value | $16.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.78 | −$3.79 | $0.55 | $0.55 | — | −$5.51 |
| 2017 | $3.19 | −$4.18 | $0.91 | −$6.04 | — | −$8.46 |
| 2018 | $1.67 | −$4.95 | $1.30 | −$5.38 | — | — |
| 2019 | $0.18 | −$1.55 | $0.10 | −$1.48 | — | $3.49 |
| 2020 | $2.11 | −$1.96 | $0.18 | $5.14 | — | $6.42 |
| 2021 | $42.86 | $28.31 | $0.66 | $30.94 | — | $35.10 |
| 2022 | $46.31 | $20.10 | $0.96 | $11.01 | — | $49.67 |
| 2023 | $17.93 | −$12.34 | $1.85 | −$10.01 | — | $36.27 |
| 2024 | $8.43 | −$9.27 | $2.74 | −$10.56 | — | $28.24 |
| 2025 | $5.00 | −$7.25 | $0.49 | −$5.31 | — | $21.95 |